Objective-Arterial calcification is common and contributes to the pathogenesis of occlusive vascular disease. Similar to the dynamics of bone, it is a tightly controlled process that maintains a balance between osteogenesis and osteolysis. However, whether calcium homeostasis plays a role in the development of aneurysms has not been explored. We hypothesized that macrophages differentiate into osteoclasts in aneurysmal arteries and that protease byproducts contribute to aneurysm pathophysiology. Approach and Results-We performed histological and immunohistochemical analyses and showed that macrophages positive for several osteoclast markers, including tartrate acid phosphatase, occur in great numbers in the human aneurysmal aorta, but very few occur in the human stenotic aorta and none in the nondiseased human aorta. Moreover, in situ zymography showed elevated protease activity in these cells compared with undifferentiated macrophages. Tumor necrosis factor-α and calcium phosphate stimulated this osteoclastogenic differentiation process through nuclear factor-κB, mitogen-activated protein kinases, and intracellular calcium signaling but not the receptor activator of the nuclear factor-κB ligand. Inhibition of osteoclastogenic differentiation by bisphosphonate inhibits aneurysm development in a mouse model. Conclusions-These results suggest that differentiation of macrophages into osteoclasts contributes to the pathophysiology of aneurysmal disease. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C ardiovascular disease is widely recognized as the leading cause of death in the United States. Cardiovascular diseases are usually occlusive, that is, resulting from the narrowing of blood vessels that serve the heart, other critical organs, or the extremities. Alternatively, an abdominal aortic aneurysm (AAA), which is the consequence of arterial dilatation, can be lethal. 1 Although several pharmacological therapies have been proposed to prevent AAA growth and rupture, the only clinically available treatment is surgery; thus, there is a need for additional therapeutic strategies guided by a better understanding of AAA pathophysiology. 2, 3 Calcification is a major feature of atherosclerotic cardiovascular disease. Occlusive atherosclerosis, particularly of the peripheral vessels, is often associated with heavy, rigid, and circumferential calcification. The distribution of calcium associated with aneurysmal disease, however, is different because it is characterized by a thin layer diffusely distributed throughout the arterial wall. Recent reports have revealed that artery calcification is a tightly controlled process similar to that seen in bone, with a balance maintained between osteogenesis and osteolysis. 4, 5 Osteogenesis is characterized by bone matrix deposition by osteoblasts, whereas osteolysis is the active resorption of the extracellular matrix by osteoclasts, which are derived from monocyte/macrophage lineage cells through osteoclastogenesis. The pathways involved in osteoclastogenesis have been extensively studied. 6 The receptor activator of nuclear factor κB (NFκB) ligand (RANKL) has been shown to induce osteoclastogenesis through its cognate receptor RANK. The RANKL-RANK interaction subsequently activates both tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and several downstream signaling pathways, including intracellular calcium [Ca 2+ ] i , NFκB, and mitogen-activated protein kinases (MAPKs). 7, 8 Because accelerated calcification is a major pathogenic feature of occlusive peripheral arterial disease, many studies have focused on osteogenesis. Alternatively, we hypothesized that the calcification observed in aneurysm walls is significantly less dense and is the result of pathogenic resorption of calcium (osteolysis) by osteoclasts. Because a prominent function of osteoclasts is the production of proteases, in particular, matrix metalloproteinases (MMPs), which are well-known contributors to AAA, we proposed that increased numbers of osteoclasts in the arterial wall may be an important contributor to the development of AAA.
In this study, we examined whether and how osteoclastogenesis is involved in the pathogenesis of AAA. We report that macrophages undergoing osteoclastic differentiation exist in human and mouse aneurysms and that pharmacological inhibition of osteoclastogenesis suppresses the development and progression of aneurysmal disease.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Osteoclastogenic Differentiation of Macrophages Is Observed in Aneurysmal Disease
Arterial calcification produced by calcium phosphate (CaPO 4 ) crystals is one of the key pathogenic features of atherosclerosis and is abundantly present in stenotic arteries. 9, 10 Although the pathophysiology of aneurysms differs from that of stenotic disease, we have observed calcification in human AAA specimens as well, albeit to a lesser extent than in stenotic arteries. 4 Figure 1A shows representative examples of computed tomographic scans of nondiseased aorta with little calcium, a stenotic artery with dense circumferential calcium, and an aneurysmal artery with a thin, less dense layer of calcium distributed only in a portion of the aortic wall. Histologically, we found dense calcification in the medial layer of human stenotic vessels but moderate diffuse calcification in the media of aneurysm specimens ( Figure 1A) . A similar distribution of calcification was observed in a mouse model of aneurysmal disease ( Figure I in the online-only Data Supplement). 11 Arterial calcification in stenotic arteries is tightly controlled by a balance maintained between osteogenesis, characterized by the deposition of bone matrix by osteoblasts, and osteolysis, characterized by active resorption of the extracellular matrix by osteoclasts. 4, 5, 12 Because macrophages accumulate in AAAs, we hypothesized that differentiation of macrophages into osteoclasts occurs in the aneurysmal aorta, resulting in resorption of calcium and a thinning of the calcified layer. A byproduct of this process might be increased proteolytic activity, with extracellular matrix degeneration leading to aneurysmal degeneration. 2, 3 Osteoclasts are histologically defined as multinucleated cells that stain positive for tartrate-resistant acid phosphate (TRAP) 13 and are called osteoclast-like cells if they exist in tissues other than bone. 14 Human aneurysmal, stenotic, and nondiseased aortic tissues were stained for TRAP. TRAPpositive cells were identified only in human aneurysmal aorta (100% of samples, N=8) and not in stenotic (N=5) or nondiseased aorta (N=3; Figure 1B ; Figures II and III in the online-only Data Supplement). TRAP-positive cells were also abundant in the mouse aneurysm model (100% of samples, N=10; Figure 1C ). On the contrary, ALP (alkaline phosphatase; an osteoblast marker)-positive cells (stained red) were observed in the vascular intima in the mouse aneurysm model ( Figure IV in the online-only Data Supplement). Because our hypothesis is that macrophages transition into osteoclast-like cells in aneurysmal tissues, we stained human aneurysm tissue with CD68 (a marker for macrophages), TRAP, and a calcitonin receptor (CTR; a secondary marker for osteoclast-like cells). 15, 16 Sideby-side staining of TRAP, CD68, and CTR revealed clusters of TRAP-positive cells also positive for CD68 and CTR in human aneurysm ( Figure 1D ). To further delineate the relative ratio of macrophages (CD68 + CTR − cells) and osteoclast-like cells (CD68 + CTR + cells) in aneurysmal versus stenotic tissues, we performed a flow cytometry analysis of cells disassociated from human specimens, although it is difficult to compare intracellular staining for CD68 with cell surface staining for CTR. We found a significantly greater number of macrophages (CD68 + CTR − ) and osteoclast-like cells (CD68 + CTR + ) in aneurysms (18.6% CD68 + CTR − cells and 10.3% CD68 + CTR + cells, respectively) than in stenotic vessels (5.1% and 1.8%, respectively; Figure 1E ). Thus, 55% of the macrophages in aneurysmal tissue underwent osteoclastogenic differentiation. Taken together, these results demonstrate the significant activity of osteoclast-like cells in human and mouse aneurysmal tissues, with minimal osteoclast-like activity in stenotic disease.
TNFα Plus CaPO 4 -Induced Osteoclastogenesis In Vitro
The TNFα pathway as well as the RANKL pathway and its downstream signaling have previously been shown to be involved in osteoclastogenesis. 17, 18 To explore the mechanisms of osteoclastogenesis in aneurysms, immunohistochemical staining of RANKL, osteoprotegerin, a natural decoy receptor of RANKL, and TNFα were performed in human nondiseased, stenotic, and aneurysmal tissues and mouse aneurysms. Immunohistochemical staining showed an absence of RANKL and osteoprotegerin in all of these tissues, suggesting that the RANK ligand does not play a role in osteoclastogenesis in aneurysms. The inflammatory cytokine, TNFα (Figures V and VI in the online-only Data Supplement), was minimally enhanced in stenotic tissues but significantly enhanced in human and mouse aneurysms. There was also a significant increase in TNFα according to Western blotting ( Figure VII in the online-only Data Supplement). We evaluated other cytokines known to be involved in AAA, but we did not observe an enhancement of MCP-1 (monocyte chemoattractant protein-1) or interleukin-1β that was as significant as that of TNFα ( Figure VIII in the online-only Data Supplement).
We expanded on this analysis using an in vitro osteoclastogenesis assay using primary cultured and RAW 264.7 mouse macrophages. To explore the role of TNFα in stimulating osteoclastogenesis, we stimulated both types of macrophages with TNFα and observed a minimal enhancement of osteoclastogenesis. We previously reported that CaPO 4 As shown in Figure 2A and 2B and Figures IX and X in the online-only Data Supplement, CaPO 4 alone (mimicking stenotic aorta) produced minimal osteoclastogenesis in both macrophage cell types, whereas costimulation of macrophages with CaPO 4 plus TNFα (mimicking aneurysmal tissue) yielded TRAP-positive multinucleated cells stained purplered and an increased cell number. We also observed robust, dose-dependent osteoclastogenesis, as measured by TRAP ( Figure XI in the online-only Data Supplement). Furthermore, the combination of TNFα and CaPO 4 induced Trap (also known as Acp5) mRNA 3 days after treatment ( Figure 2C ). We also confirmed that CaPO 4 and TNFα induced expression of cathepsin K (Ctsk) as well as the CTR (Calcr; Figure 2D and 2E). Moreover, the nuclear factor of activated T cells cytoplasmic 1 (NFATc1), an essential transcription factor for osteoclastogenesis, increased 2-fold by the cotreatment of cells with TNFα plus CaPO 4 ( Figure 2F ).
To explore the involvement of classical osteoclastogenesis pathways through the RANK ligand and receptor, macrophages were stimulated with CaPO 4 and TNFα or RANKL in the presence of neutralizing antibodies to mouse RANKL. Although RANKL-induced osteoclastogenesis and NFATc1 expression were completely inhibited by the RANKL-neutralizing antibody, TNFα plus CaPO 4induced osteoclastogenesis and NFATc1 expression were not affected ( Figure 2G and 2H). Taken together, these findings demonstrate that the combination of TNFα and CaPO 4 stimulates macrophage osteoclastogenesis; however, the mechanism is not dependent on the RANKL-RANK pathway.
Signaling Pathway in TNFα Plus CaPO 4 -Induced Osteoclastogenesis
Conventionally, osteoclastogenesis is triggered by RANKL through the TRAF6 signaling pathway ( Figure XII in the online-only Data Supplement). 19 Thus, we initially investigated TRAF6 levels in TNFα plus CaPO 4 -induced osteoclastogenesis. Consistent with our RANKL findings, neither the TNFα nor the TNFα plus CaPO 4 treatments affected TRAF6 mRNA expression ( Figure 3A levels were found to be significantly elevated ( Figure 3B ). To establish the specific role of Traf2 in the transformation of macrophages into osteoclasts, we blocked Traf2 expression with siRNA. Inhibition of Traf2 significantly suppressed TNFα plus CaPO 4 -induced osteoclastogenesis ( Figure 3C ). To further evaluate the downstream signaling involved in TNFα plus CaPO 4 osteoclastogenesis, we then focused on NFκB and MAPK, both pathways that are involved in the RANK-TRAF6 axis. The TNFα treatment significantly increased IκBα phosphorylation levels measured by Western blotting (Figure 3D ), as well as nuclear translocation of NFκB p65 ( Figure 3E ), which was not further enhanced by TNFα plus CaPO 4 . These results suggest that TNFα induces nuclear translocation of NFκB p65 by activating IκBα phosphorylation and degradation. Phosphorylation of p38 MAPK was significantly enhanced by TNFα but not further enhanced by TNFα plus CaPO 4 ( Figure 3F ). Phosphorylated JNK levels also increased after TNFα treatment. Interestingly, phosphorylated JNK levels were higher in the TNFα plus CaPO 4 treatment versus the TNFα treatment alone ( Figure 3G ), suggesting a synergistic effect of CaPO 4 on JNK phosphorylation. 20 Furthermore, as shown in Figure XIII in the onlineonly Data Supplement, we performed Western blot analysis to determine the effect of siTraf2 on the phosphorylation levels of IκB, p38, and JNK in RAW 264.7 cells. The phospho-IκB and p38 levels induced by TNFα plus CaPO 4 treatment were significantly decreased by siTraf2. The TNFα plus CaPO 4induced phospho-JNK levels tended to decrease, but not significantly, in response to siTraf2. These results suggest that TNFα, using TRAF2 instead of the more traditional pathway of TRAF6, activates downstream NFκB, p38 MAPK, and JNK to induce osteoclastogenesis.
TNFα Plus CaPO 4 -Induced Intracellular Calcium Signaling Pathway
Intracellular calcium signaling is another important downstream mechanism involved in RANKL-induced osteoclastogenesis. 21 As shown in Figure XIV in the online-only Data Supplement and Figure 4A , [Ca 2+ ] i was significantly increased by treatment of macrophages with CaPO 4 but not further enhanced with TNFα. Enhancement of [Ca 2+ ] i leads to activation of Ca 2+ /calmodulin kinase IV (CaMKIV) and the phosphatase, calcineurin. In turn, CaMKIV activates NFATc1 through a pathway mediated by the transcription factor cAMP response element-binding protein, whereas calcineurin has been shown to activate NFATc1 directly. 6 In macrophages, phosphorylation of CaMKIV is significantly enhanced by TNFα plus CaPO 4 treatment compared with control. The addition of TNFα with CaPO 4 led to synergistic induction of the phosphorylation of CaMKIV, indicating a possible interaction between TNFα and CaMKIV ( Figure 4B ). 22 Calcineurin was also significantly increased by TNFα plus CaPO 4 treatment compared with TNFα treatment alone ( Figure 4C ). To clarify whether activation of [Ca 2+ ] i signaling with TNFα is sufficient to induce osteoclastogenesis, ionomycin was added to RAW 264.7 cells with TNFα. Ionomycin treatment markedly stimulated TNFα plus CaPO 4 -induced osteoclast differentiation compared with TNFα treatment alone ( Figure 4D ). Intracellular NFATc1 expression also increased by 1.9-fold by TNFα plus ionomycin treatment compared with TNFα treatment alone ( Figure 4E ). To further examine the involvement of [Ca 2+ ] i signaling in TNFα plus CaPO 4 -induced osteoclastogenesis, the effects of pyrophosphate, an inhibitor of CaPO 4 , were examined. 23 Pyrophosphate treatment suppressed TNFα plus CaPO 4 -induced osteoclastogenesis, as well as NFATc1 expression levels in a dose-dependent manner ( Figure 4F and 4G ). As shown in Figure XV 
Upregulation of Protease Activity by Osteoclastogenesis in an Aneurysm
MMP-9 is mostly secreted from macrophages and has been recognized as an important factor in the development of aneurysms. 24 Because osteoclasts also have an abundant source of MMPs, 25 we evaluated whether Mmp9 expression and secretion of MMP-9 increased in macrophages (RAW 264.7 cells) treated with TNFα and with or without CaPO 4 . As shown in Figure 5A , Mmp9 expression was enhanced by TNFα plus CaPO 4 treatment in a time-dependent manner. The pattern of Mmp9 expression was similar to that of Trap, as shown in Figure 2C . Corresponding to Mmp9 expression, MMP-9 secretion was markedly facilitated by 5 days of treatment with TNFα plus CaPO 4 (a 2.6-fold increase versus TNFα alone; Figure 5B ). This increase in MMP-9 secretion was suppressed by a pretreatment with the CaPO 4 inhibitor, pyrophosphate ( Figure 5C ). To investigate whether the MMP-9 activity associated with osteoclast-like cells is higher than that of undifferentiated macrophages, we next examined MMP-9 activity in TRAP-positive cells versus non-TRAP-positive macrophages using in situ zymography of a human aneurysmal aorta. After selecting the locations of TRAP-positive cells and non-TRAP-positive macrophages by dual staining of TRAP and CD68, we performed in situ zymography and quantified MMP-9 activity by the relative fluorescence intensity. As shown in Figure 5D and Figure produced significantly greater MMP-9 activity compared with non-TRAP-positive macrophages in a human aneurysmal aorta. These results demonstrate an increased protease activity by osteoclast-like cells compared with the undifferentiated macrophages in a human aneurysmal aorta.
Pharmacological Inhibition of Osteoclastogenesis Suppressed Aneurysm Formation
Pharmacological inhibition of osteoclastogenesis uses bisphosphonate for the clinical treatment of osteoporosis. 26, 27 Bisphosphonate binds to CaPO 4 and locally inhibits osteoclast activity and osteoclastogenesis. 28 We hypothesized that controlling the formation and activity of osteoclasts might be an effective strategy for inhibiting aneurysms. Zoledronic acid (ZA) is a nitrogenous bisphosphonate that produces apoptosis of osteoclast-like cells and also interferes with osteoclastogenesis. As shown in Figure 6A -6C, ZA, in a dose-dependent manner, inhibited TNFα plus CaPO 4 -induced osteoclastogenesis in vitro and mouse aneurysm formation in vivo, with a nearly complete inhibition of aneurysms at a concentration of 100 μg/kg, which is equivalent to the clinically approved ZA dose of 50 to 100 μg/kg. TRAP staining of vehicle-treated and bisphosphonate-treated mouse aneurysms showed a near complete inhibition of osteoclastogenesis by bisphosphonate treatment.
Discussion
Osteoclast-like cells are defined as multinucleated giant cells that share morphological and histological characteristics with osteoclasts but exist in tissues other than bone. 14 Here we confirm the existence of numerous osteoclast-like cells in both human and mouse aneurysms but very few in stenotic tissues and none in nondiseased aortic tissue. Macrophages were more prevalent in aneurysmal than in stenotic aorta, and almost half of the macrophages had undergone osteoclastogenic differentiation in aneurysms. Although these cells were TRAP-positive, conventional osteoclasts are generally larger in size and with more ruffled borders than the cells we observed, indicating that the macrophages in these aneurysms had undergone osteoclastogenic differentiation. However, the end products of osteoclast-like cells were still distinct from conventional osteoclasts.
To investigate the factors that stimulated this transformation, we screened several cytokines and found elevated TNFα levels in aneurysmal tissue. Further studies revealed that TNFα stimulated osteoclast-like cell formation in vivo. We also identified a novel feedback loop where CaPO 4 crystals and TNFα synergistically induced osteoclastogenesis. With regard to signaling, we initially focused on the RANKL-osteoprotegerin pathway, which has been shown to activate TRAF6 and calcium, ultimately leading to the activation of NFATc1, a transcription factor essential for osteoclastogenesis. 29 However, we were not able to demonstrate upregulation of RANKL or osteoprotegerin in aneurysmal tissue. Instead, we identified an alternative pathway independent of RANKL induced by TNFα and CaPO 4 and involving TRAF2. Downstream effectors from TRAF2 were similar to those of TRAF6 and included NFκB, MAPK, and intracellular Ca 2+ . 23, 29 Even when IκB was phosphorylated, the levels of IκB were unchanged. The translocation of NFκB to the nucleus was accompanied by the phosphorylation, ubiquitination, and proteasomal degradation of IκBa. Therefore, the opposite trend to that observed in the levels of p-IκB was often observed in the levels of IκB, which may be increased by TNFa plus CaPO 4 stimulation for 48 hours. Traf2 protein expression and the phosphorylation levels of CaMKIV were significantly increased in AAA patient sections compared with normal human sections. These results support the in vitro results and suggest, but do not conclusively prove, the involvement of osteoclastogenesis in AAA development. Further studies are needed to show direct evidence that this is a mechanism underlying the development of AAA.
Because osteoclasts have been identified as an important source of protease during osteolysis, we hypothesized that the TRAP-positive cells contribute to aneurysm formation through their active production of proteases. Among the many proteases, MMP-9 has proven to be one of the most important in aneurysm formation and development. 24, 30, 31 Our in vitro results demonstrate that TRAP-positive macrophages show an almost 8-fold increase in MMP-9 expression relative to TRAP-negative macrophages. In situ zymography consistently revealed higher MMP-9 activity associated with TRAP-positive versus TRAP-negative macrophages in human aneurysmal tissue. Our results from the mouse aneurysm model showed an almost complete inhibition of aneurysm formation as well as inhibition of further expansion of existing aneurysms by the osteoclast inhibitor bisphosphonate. Although a direct effect of bisphosphonate on non-TRAPpositive macrophages cannot be fully excluded, inhibition of osteoclastogenesis seems to be a potentially important therapeutic target for aneurysms. 32 We repeated our studies with bisphosphonate in an alternative AAA model induced by angiotensin II. ZA binds to CaPO 4 and exerts a suppressive effect on osteoclastogenesis. It usually requires only a single intravenous injection per year in human, and we, therefore, examined the effect of a single injection of ZA in angiotensin II-induced AAA. However, in contrast to Tsai et al, we found no suppression of AAA ( Figure XX in the online-only Data Supplement). 4, 33, 34 These differing results may be because of the amount of ZA binding to CaPO 4 . We also speculate that the absence of a bisphosphonate effect is related to the lack of overt arterial calcification in aneurysms in this model. Nistala et al also reported negative results for bisphosphonate on aneurysm progression in Marfan syndrome using Fbn1 (mgR/ mgR) mice. 33, 35 Because Fbn1 mice more closely mimic connective tissue disorders, such as Marfan syndrome, we think that the underlying mechanism in this model differs from the pathophysiology of the traditional AAA model.
In females, there is a steep increase in aneurysmal disease and aneurysm rupture and a significant increase in osteoporosis after menopause. 1 It may be that both are related to an enhancement of osteoclast activity in the absence of estrogen. These findings suggest a suppressive effect of estrogen on aneurysm formation, possibly through the inhibition of osteoclastogenesis. We evaluated 3 large clinical data sets to see whether we could determine a relationship between bisphosphonate treatment (which is frequent in postmenopausal women) and the development of aneurysms. Unfortunately, we were not able to obtain a sufficient sample size to establish a relationship. For this reason, a prospective randomized clinical trial to test the effect of bisphosphonate on aneurysms is warranted. If this trial was positive, medical treatment with bisphosphonate would be simple and associated with few complications. Moreover, unlike other pharmacological treatments that require daily dosing, the latest generations of bisphosphonates are effective, with as few as one intravenous injection per year, which could be performed in conjunction with yearly aneurysm screening. 26, 27 We focused on the differentiation of macrophages into osteoclasts in the pathogenesis of AAA. Recent reports have revealed that artery calcification is a tightly controlled process similar to that seen in bone, with a balance maintained between osteogenesis and osteolysis, and there have been no reports of osteoclastogenesis in AAA. Although we have not determined the extent of calcification and changes in osteoblast-like cells in the pathogenesis of AAA, Nakayama et al 36 reported that a lower extent of calcification correlated with accelerated expansion of AAA, which may be consistent with our results. However, Buijs et al 37 found a trend of increased abdominal aortic calcification in patients with aortic rupture. Therefore, additional research comparing osteoclasts and osteoblasts is needed to clarify the relation between expansion, calcification, and rupture in AAA.
We used a modified CaCl 2 model in which topical application of CaCl 2 is followed by PBS, which may create the conditions for forming CaPO 4 crystals locally. As described earlier, there was no calcification in alternative AAA models, such as the one generated by angiotensin II infusion. Thus, further experiments are required to demonstrate whether our findings in this study are model-specific by repeating the experiments in additional models, such as the porcine pancreatic infusion model. Similarly, after application of CaCl 2 to the adventitia of the abdominal aorta, aortic dilatation was reportedly accompanied by elastin calcification, loss of vascular smooth muscle cells, and marked infiltration of inflammatory cells, such as neutrophils, lymphocytes, monocytes, and multinucleated giant cells, 38 leading to induction of AAA. The possible physiological differences between these anatomic structures make the carotid artery an imperfect model and are a limitation of this study.
In summary, we have shown conclusively that osteoclastogenic differentiation of macrophages plays an important role in the development of AAAs through novel stimuli (TNFα and CaPO 4 ) and a host of downstream signaling effectors. Thus, inhibiting this process could prove to be a novel therapeutic approach to the treatment of aneurysmal disease.
